Amycretin — compound monograph
Unimolecular amylin and GLP-1 receptor co-agonist. Phase 2. The Institute assesses 1 outcome for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Amycretin
- Compound class
- Unimolecular amylin and GLP-1 receptor co-agonist
- Assessment series
- Combinations and unimolecular co-agonists
- Synonyms and codes
- NNC0487-0111 · amycretin (INN)
- Route as evaluated
- Subcutaneous once weekly, and oral once daily in a parallel programme
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- not assigned in public records
- Molecular formula
- not published
- Average mass
- not published
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Amycretin differs from CagriSema in being one molecule rather than a co-formulation of two, which removes the content-ratio quality attribute but introduces the analytical challenge of characterising a chimeric sequence with no natural parent.
§1.4Assessment status
The Institute assesses Amycretin across 1 indication and grades the strongest of them at low certainty. In exploratory clinical development.
Table 1. Assessed outcomes for Amycretin, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −13.1 % body weight at 12 weeks in a phase 1b subcutaneous study versus −1.1 % with placebo | Low | 3 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.